{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:42:50Z","timestamp":1771008170910,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1136\/ard.59.suppl_1.i46","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:45:32Z","timestamp":1027766732000},"page":"i46-i49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"S1","title":["Etanercept (Enbrel): update on therapeutic use"],"prefix":"10.1016","volume":"59","author":[{"given":"George","family":"Spencer-Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.59.suppl_1.i46_bib1","first-page":"165","article-title":"Etanercept: therapeutic use in patients with rheumatoid arthritis.","volume":"58 (suppl 1)","author":"Garrison","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.59.suppl_1.i46_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/319516a0","article-title":"Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.","volume":"319","author":"Bertolini","year":"1986","journal-title":"Nature"},{"key":"10.1136\/ard.59.suppl_1.i46_bib3","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","article-title":"Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.","volume":"162","author":"Dayer","year":"1985","journal-title":"J Exp Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib4","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1210\/endo.139.7.6085","article-title":"Prostaglandin E2, interleukin 1\u03b1, and tumor necrosis factor-\u03b1 increase human osteoclast formation and bone resorption in vitro.","volume":"139","author":"Lader","year":"1998","journal-title":"Endocrinology"},{"key":"10.1136\/ard.59.suppl_1.i46_bib5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.163.6.1363","article-title":"Tumor necrosis factor\/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.","volume":"163","author":"Nawroth","year":"1986","journal-title":"J Exp Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib6","first-page":"225","article-title":"Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.","volume":"6","author":"Butler","year":"1995","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.59.suppl_1.i46_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.","volume":"ii","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.59.suppl_1.i46_bib8","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.","volume":"151","author":"Mohler","year":"1993","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.suppl_1.i46_bib9","first-page":"S369","article-title":"Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion.","volume":"42","author":"Barone","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.suppl_1.i46_bib10","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.4049\/jimmunol.151.11.6602","article-title":"Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice.","volume":"151","author":"Wooley","year":"1993","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.suppl_1.i46_bib11","first-page":"1849","article-title":"Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.","volume":"23","author":"Moreland","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.59.suppl_1.i46_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.59.suppl_1.i46_bib16","first-page":"S401","article-title":"Long-term use of Enbrel in patients with DMARD-refractory rheumatoid arthritis.","volume":"42","author":"Moreland","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.suppl_1.i46_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.47.1.5","article-title":"Cancer statistics, 1997.","volume":"47","author":"Parker","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ard.59.suppl_1.i46_bib18","first-page":"S117","article-title":"A Phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial).","volume":"42","author":"Finck","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.suppl_1.i46_bib19","first-page":"S81","article-title":"Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials.","volume":"42","author":"Schiff","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.suppl_1.i46_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score.","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.59.suppl_1.i46_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis.","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.suppl_1.i46_bib22","first-page":"712","article-title":"Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.","volume":"26","author":"Pham","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.59.suppl_1.i46_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Randomized trial of etanercent (Enbrel) in the treatment of psoriatic arthritis and psoriasis.","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.59.suppl_1.i46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:15:51Z","timestamp":1737267351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724498889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":23,"alternative-id":["S0003496724498889"],"URL":"https:\/\/doi.org\/10.1136\/ard.59.suppl_1.i46","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept (Enbrel): update on therapeutic use","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.59.suppl_1.i46","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}